Literature DB >> 6103724

Effects of sulphasalazine and its metabolites on prostaglandin synthesis, inactivation and actions on smooth muscle.

J R Hoult, P K Moore.   

Abstract

1 We have investigated the effects of sulphasalazine and of its principal colonic metabolites (5-aminosalicylic acid and sulphapyridine) on prostaglandin inactivation, synthesis and actions on gastrointestinal smooth muscle.2 Sulphasalazine inhibits prostaglandin F(2alpha) breakdown in 100,000 g supernatants in all organs so far tested from 7 species with an ID(50) of approx. 50 muM; it has a selective action on prostaglandin 15-hydroxydehydrogenase and does not inhibit prostaglandin Delta-13 reductase, prostaglandin 9-hydroxydehydrogenase or ;enzyme X' at millimolar concentrations. Enzyme activities were measured radiochemically or by bioassay.3 Sulphapyridine and 5-aminosalicylic acid do not inhibit prostaglandin inactivation in vitro (4 species tested). A methyl analogue of sulphasalazine is a more potent inhibitor than the parent compound. Rabbit colon prostaglandin F(2alpha) metabolism in vitro was inhibited by the following drugs with ID(50) values (muM) of: diphloretin phosphate 20, sulphasalazine 50, indomethacin 220, frusemide 1000 and aspirin 10,000. A similar rank order of potencies was obtained with rabbit kidney.4 Sulphasalazine at 50 to 100 muM inhibited inactivation of prostaglandin E(2) in the perfused rat and guinea-pig lung by 3 to 40% (rat) and 32 to 100% (guinea-pig) when measured by superfusion cascade bioassay and of prostaglandin F(2alpha) by 43.6 +/- 6.5% in rat lung perfused with 50 muM sulphasalazine and assayed radiochemically.5 Prostaglandins E(1) and E(2) were 97.0 +/- 8.2% and 92.3 +/- 6.8% inactivated in the lungs after intravenous injection in the anaesthetized rat as measured by reference to their vasodepressor potencies when injected intra-arterially. Prostaglandin A(2) was not similarly inactivated. Pulmonary inactivation was prevented in the presence of an intravenous infusion of 16.3 mug kg(-1) min(-1) sulphasalazine and partially inhibited at a lower infusion rate.6 Prostaglandin biosynthesis from arachidonic acid was measured in microsomal preparations from four sources by bioassay and radiochemical methods. Indomethacin was a potent inhibitor (ID(50) 0.8 to 4.1 muM) but sulphasalazine and its methyl analogue were very weak inhibitors (ID(50) 1500 to > 5000 muM), 5-aminosalicylic acid was weaker still and sulphapyridine inactive.7 Sulphasalazine at 50 muM did not affect the actions of prostaglandins on five smooth muscle preparations; at 500 muM there was a rapidly reversible and probably non-specific antagonism of responses to low doses of prostaglandins.8 The specificity and selectivity of the interaction of sulphasalazine and its metabolites with the formation, breakdown and actions of prostaglandins are discussed.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6103724      PMCID: PMC2044233          DOI: 10.1111/j.1476-5381.1980.tb10865.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  36 in total

Review 1.  Biosynthesis of prostaglandins.

Authors:  B Samuelsson
Journal:  Fed Proc       Date:  1972 Sep-Oct

2.  The effect of anti-inflammatory drugs on vascular smooth muscle.

Authors:  B J Northover
Journal:  Br J Pharmacol Chemother       Date:  1967-11

Review 3.  The release and fate of vaso-active hormones in the circulation.

Authors:  J R Vane
Journal:  Br J Pharmacol       Date:  1969-02       Impact factor: 8.739

4.  15-Hydroxy-prostanoate dehydrogenase. Prostaglandins as substrates and inhibitors.

Authors:  J Nakano; E Anggård; B Samuelsson
Journal:  Eur J Biochem       Date:  1969-12

5.  Metabolism of prostaglandin E 2 in guinea pig liver.

Authors:  M Hamberg; U Israelsson; B Samuelsson
Journal:  Ann N Y Acad Sci       Date:  1971-04-30       Impact factor: 5.691

6.  Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs.

Authors:  J R Vane
Journal:  Nat New Biol       Date:  1971-06-23

7.  The sequence of the early steps in the metabolism of prostaglandin E1.

Authors:  E Anggård; C Larsson
Journal:  Eur J Pharmacol       Date:  1971       Impact factor: 4.432

8.  Drugs which inhibit prostaglandin biosynthesis.

Authors:  R J Flower
Journal:  Pharmacol Rev       Date:  1974-03       Impact factor: 25.468

9.  Interaction of prostaglandins with blood plasma proteins. Comparative binding of prostaglandins A 2 , F 2 and E 2 to human plasma proteins.

Authors:  A Raz
Journal:  Biochem J       Date:  1972-11       Impact factor: 3.857

10.  Prostaglandins A1,A2 and 19-hydroxy A1; their actions on smooth muscle and their inactivation on passage through the pulmonary and hepatic portal vascular beds.

Authors:  E W Horton; R L Jones
Journal:  Br J Pharmacol       Date:  1969-11       Impact factor: 8.739

View more
  18 in total

Review 1.  Sulfasalazine. Multiplicity of action.

Authors:  T S Gaginella; R E Walsh
Journal:  Dig Dis Sci       Date:  1992-06       Impact factor: 3.199

Review 2.  Inflammatory intermediaries in inflammatory bowel disease.

Authors:  K Lauritsen; L S Laursen; K Bukhave; J Rask-Madsen
Journal:  Int J Colorectal Dis       Date:  1989       Impact factor: 2.571

Review 3.  Sulphasalazine in ulcerative colitis: in memoriam?

Authors:  J Hayllar; I Bjarnason
Journal:  Gut       Date:  1991-05       Impact factor: 23.059

Review 4.  Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease.

Authors:  S B Hanauer; G Stathopoulos
Journal:  Drug Saf       Date:  1991 May-Jun       Impact factor: 5.606

5.  5-Aminosalicylic acid concentration in mucosal interstitium of cat small and large intestine.

Authors:  M B Grisham; D N Granger
Journal:  Dig Dis Sci       Date:  1989-04       Impact factor: 3.199

6.  Sulphasalazine and experimental stress ulcers.

Authors:  C W Ogle; C H Cho; S Dai
Journal:  Agents Actions       Date:  1985-12

7.  Ulcerative colitis: effect of sulphasalazine, its metabolites and indomethacin on the ability of human colonic mucosa to metabolize prostaglandins in vitro.

Authors:  K Hillier; P J Mason; S Pacheco; C L Smith
Journal:  Br J Pharmacol       Date:  1982-05       Impact factor: 8.739

8.  Increased suppressor cell activity in inflammatory bowel disease.

Authors:  G Holdstock; B F Chastenay; E L Krawitt
Journal:  Gut       Date:  1981-12       Impact factor: 23.059

9.  Effects of sulphasalazine and disodium azodisalicylate on colonic PGE2 concentrations determined by equilibrium in vivo dialysis of faeces in patients with ulcerative colitis and healthy controls.

Authors:  K Lauritsen; J Hansen; P Bytzer; K Bukhave; J Rask-Madsen
Journal:  Gut       Date:  1984-11       Impact factor: 23.059

10.  Effect of sulphasalazine and its metabolites on the generation of reactive oxygen species.

Authors:  Y Miyachi; A Yoshioka; S Imamura; Y Niwa
Journal:  Gut       Date:  1987-02       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.